NEXT-GENERATION GLP-1 PHARMACOTHERAPY: ADVANCES IN OBESITY TREATMENT WITH CONSIDERATIONS FOR PHYSICAL PERFORMANCE AND POPULATION HEALTH

Bartosz Skorupski; Dominika Nowak; Aleksandra Gradek; Marcin Sawczuk; Jan Noskowicz; Jan Urban; Julia Konat; Patrycja Długosz; Anna Gryc; Mathias Spitaleri

doi:10.31435/ijitss.3(47).2025.3678

Bartosz Skorupski Independent Public Health Care Facility in Puławy, ul. Józefa Bema 1, 24-100 Puławy, Poland https://orcid.org/0009-0003-3314-983X
Dominika Nowak University Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland https://orcid.org/0000-0002-0195-1102
Aleksandra Gradek University Clinical Center in Gdańsk, ul. Dębinki 7, 80-952 Gdańsk, Poland https://orcid.org/0009-0000-5112-3439
Marcin Sawczuk University Clinical Center in Gdańsk, ul. Dębinki 7, 80-952 Gdańsk, Poland https://orcid.org/0009-0003-1204-0624
Jan Noskowicz Independent Public Healthcare Institution of the Ministry of Internal Affairs and Administration named after Sergeant Grzegorz Załoga in Katowice, ul. Wita Stwosza 39/41, 40-042 Katowice, Poland https://orcid.org/0009-0009-6578-0398
Jan Urban Independent Public Healthcare Institution of the Ministry of Internal Affairs and Administration named after Sergeant Grzegorz Załoga in Katowice, ul. Wita Stwosza 39/41, 40-042 Katowice, Poland https://orcid.org/0009-0004-8583-6970
Julia Konat Provincial Specialist Hospital in Lublin, Krasnickie Avenue 100, 20-718 Lublin, Poland https://orcid.org/0009-0008-6607-6725
Patrycja Długosz University Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland https://orcid.org/0000-0003-4517-4832
Anna Gryc University Clinical Hospital No. 4 in Lublin, ul. Doktora Kazimierza Jaczewskiego 8, 20-090 Lublin, Poland https://orcid.org/0000-0002-6258-1168
Mathias Spitaleri 7th Naval Hospital in Gdańsk, ul. Polanki 117, 80-305 Gdańsk, Poland https://orcid.org/0009-0007-0293-1764

DOI: https://doi.org/10.31435/ijitss.3(47).2025.3678

Keywords: Obesity, Glucagon-Like Peptide 1, Public Health, Sports Performance, Energy Metabolism

Abstract

Introduction and aim of the study: Obesity is a global health issue increasing risks for various diseases and straining healthcare systems. Traditional treatments often prove ineffective, spurring interest in new therapies. GLP-1 receptor agonists have emerged as promising options for treating obesity, gaining attention for their benefits on physical performance and body composition. The aim of this study is to review current knowledge on the mechanisms of action, clinical efficacy, and safety of GLP-1 receptor agonists in obesity treatment, including their implications for public health and potential relevance in physically active populations.

Review methods: A literature review was conducted using databases such as PubMed and Google Scholar. The search included keywords like: Obesity; Glucagon-Like Peptide 1; Public Health; Sports Performance; Energy Metabolism.

Current state of knowledge: GLP-1 receptor agonists can reduce body weight by 10–21% while decreasing risks of metabolic complications, such as type 2 diabetes and cardiovascular issues. Besides their primary effects, they also regulate appetite, enhance fat oxidation, and improve energy efficiency, attracting interest from physically active individuals looking to optimize body composition. Their action mechanisms include delayed gastric emptying, increased satiety, and enhanced insulin sensitivity.

Summary: The use of GLP-1 receptor agonists marks significant progress in obesity treatment with vital public health benefits. However, their off-label use among athletes raises ethical and safety concerns, especially regarding potential lean body mass loss affecting performance.

References

Swinburn BA, Kraak VI, Allender S, et al. (2019). The global syndemic of obesity, undernutrition, and climate change: The Lancet Commission report. Lancet. 393(10173):791-846. https://doi.org/10.1016/S0140-6736(18)32822-8.

Bluher M. (2019). Obesity: global epidemiology and pathogenesis. Nature Reviews Endocrinology. 15(5):288-298. https://doi.org/10.1038/s41574-019-0176-8.

Drucker DJ. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 57:101351. https://doi.org/10.1016/j.molmet.2021.101351.

Muller TD, Finan B, Bloom SR, et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 30:72-130. https://doi.org/10.1016/j.molmet.2019.09.010.

Campbell JE, Drucker DJ. (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17(4):753–768. https://doi.org/10.1016/j.cmet.2013.04.008.

Ramracheya R, Ward C, Shigeto M, et al. (2018). GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca²⁺ channels. Diabetes. 67(3):412-422. https://doi.org/10.14814/phy2.13852.

Dong Y, Carty J, Goldstein N, He Z, et al. (2021). Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo. Molecular Metabolism. 54:101352. https://doi.org/10.1016/j.molmet.2021.101352.

Knakker B, Inkeller J, Kovács P, Lakatos PL, Szalay F, Takács I, Tóth M, Várkonyi T, Zámbó K, Zsiborás C. (2025). GLP-1 receptor agonist exenatide uncouples food intake from hedonic and anticipatory regulation in non-human primates: insights from an operant meal schedule paradigm. Neuropsychopharmacology. 50(1):410-418. https://doi.org/10.1038/s41386-024-01981-5.

Murthy TA, Chapman M, Jones KL, Marathe CS, Rayner CK, Wu T, Horowitz M. (2023). Inter-relationships between gastric emptying and glycaemia: Implications for clinical practice. World Journal of Diabetes. 14(5):447-459. https://doi.org/10.4239/wjd.v14.i5.447.

Knudsen LB. (2021). The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 12:620379. https://doi.org/10.3389/fendo.2019.00155.

Frias JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 385(6):503-515. https://doi.org/10.1056/NEJMoa2107519.

Skrobucha A, Pindlowski M, Krajewska A, Lisowska A, Musialik J, Kolackov K, Loboz-Rudnicka M. (2024). Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in cardiovascular disease. Frontiers in Cardiovascular Medicine. 11:1446468. https://doi.org/10.3389/fcvm.2024.1446468.

Pi-Sunyer X, Astrup A, Fujioka K, et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 373(1):11-22. https://doi.org/10.1056/NEJMoa1411892.

Wilding JPH, Batterham RL, Calanna S, Davies M, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 384(11):989-1002. https://doi.org/10.1056/NEJMoa2032183.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 387(3):205-216. https://doi.org/10.1056/NEJMoa2206038.

Davies M, Faerch L, Jeppesen OK, Pakseresht A, Pedersen SD, et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 397(10278):971-984. https://doi.org/10.1016/S0140-6736(21)00213-0.

Hall KD, Kahan S. (2018). Maintenance of lost weight and long-term management of obesity. Medical Clinics of North America. 102(1):183-197. https://doi.org/10.1016/j.mcna.2017.08.012.

Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. (2016). Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. Journal of the American Medical Association. 315(22):2424-2434. https://doi.org/10.1001/jama.2016.7602.

Granhall C, Donsmark M, Blicher TM, Golor G, Søndergaard FL, Thomsen M, Böttcher SG. (2019). Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clinical Pharmacokinetics. 58(6):781-791. https://doi.org/10.1007/s40262-018-0728-4.

Singh G, Krauthamer M, Bjalme-Evans M. (2022). Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine. 70(1):5-13. https://doi.org/10.1136/jim-2021-001952.

Nauck MA, Quast DR, Wefers J, Meier JJ. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 46:101102. https://doi.org/10.1016/j.molmet.2020.101102.

Hernandez AF, Green JB, Janmohamed S, et al. (2018). Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 392(10157):1519-1529. https://doi.org/10.1016/S0140-6736(18)32261-X.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 375(19):1834-1844. https://doi.org/10.1056/NEJMoa1607141.

Wharton S, Calanna S, Davies M, Dicker D, et al. (2022). Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obesity and Metabolism. 24(1):94-105. https://doi.org/10.1111/dom.14551.

Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. Journal of the American Medical Association. 325(14):1414-1425. https://doi.org/10.1001/jama.2021.3224.

le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, Machineni S, Dunn J, Chigutsa E, Ahmad NN, Wharton S. (2023). Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity. 31(1):96-110. https://doi.org/10.1002/oby.23612.

Drucker DJ. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 27(4):740-756. https://doi.org/10.1016/j.cmet.2018.03.001.

Ryan DH, Lingvay I, Colhoun HM, et al. (2020). Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. American Heart Journal. 229:61-69. https://doi.org/10.1016/j.ahj.2020.07.008.

Garvey WT, Batterham RL, Bhatta M, Buscemi S, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 28(10):2083-2091. https://doi.org/10.1038/s41591-022-02026-4.

Lingvay I, Sumithran P, Cohen RV, le Roux CW. (2022). Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 399(10322):394-405. https://doi.org/10.1016/S0140-6736(21)01919-X.

Anholm C, Kumarathurai P, Pedersen LR, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S. (2019). Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Atherosclerosis. 288:60-66. https://doi.org/10.1016/j.atherosclerosis.2019.07.007. 32. Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S. (2020). Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5. Obesity. 28(6):1050-1061. https://doi.org/10.1002/oby.22794.

Wadden TA, Bailey TS, Billings LK, Davies M, et al. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. Journal of the American Medical Association. 325(14):1403-1413. https://doi.org/10.1001/jama.2021.1831.

Fujiwara Y, Eguchi S, Murayama H, Takahashi Y, Toda M, Imai K, Tsuda K. (2019). Relationship between diet/exercise and pharmacotherapy to enhance the GLP-1 levels in type 2 diabetes. Endocrinology Diabetes and Metabolism. 2(3):e00068. https://doi.org/10.1002/EDM2.68.

Colin IM, Gérard KM. (2022). Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer? touchREVIEWS in Endocrinology. 18(1):35-42. https://doi.org/10.17925/EE.2022.18.1.35.

Bikou A, Dermiki-Gkana F, Penteris M, Constantinides T, Kontogiorgis C. (2024). A systematic review of the effect of semaglutide on Lean Mass: insights from clinical trials. Expert Opinion on Pharmacotherapy. 25(4):1-12. https://doi.org/10.1080/14656566.2024.2343092.

Ilias I, Zabulienė L, Rizzo M. (2025). GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks. Frontiers in Clinical Diabetes and Healthcare. 5:1530811. https://doi.org/10.3389/fcdhc.2024.1530811.

Biesiada W, Kopczyńska E, Kulej P, Woźniak J, Kmieć JW, Chernysh AM. (2025). Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes. Quality in Sport. 37:57025. https://doi.org/10.12775/QS.2025.37.57025.

Jensen TL, Brønden A, Karstoft K, Sonne D, Christensen MB. (2024). The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects. Patient Preference and Adherence. 18:373-382. https://doi.org/10.2147/PPA.S419304.

World Anti-Doping Agency. 2024 Monitoring Program. https://www.wada-ama.org (Access: 29.06.2025)

Morente-Sánchez J, Zabala MD. (2013). Doping in Sport: A Review of Elite Athletes' Attitudes, Beliefs, and Knowledge. Sports Medicine. 43(6):395-411. https://doi.org/10.1007/s40279-013-0037-x.

NEXT-GENERATION GLP-1 PHARMACOTHERAPY: ADVANCES IN OBESITY TREATMENT WITH CONSIDERATIONS FOR PHYSICAL PERFORMANCE AND POPULATION HEALTH

Abstract

References

Most read articles by the same author(s)